Table 2 Overall survival, progression free survival and observed complete response univariate analysis
From: DPD status and fluoropyrimidines-based treatment: high activity matters too
Overall Survival | Progression free survival | Observed complete response | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
Variable | Modality | HR | CI95% | p-Cox | HR | CI95% | p-Cox | OR | CI95% | p-RegLog |
DPD activity | Low < 0.30 | 1 | REF. | – | 1 | REF. | – | 1 | – | – |
High ≥0.30 | 3.1 | [1.50–6.50] | 0.00188 | 2.40 | [1.40–4.0] | 0.00158 | 0.34 | [0.13–0.87] | 0.022 | |
Sex | Female | 1 | REF. | – | 1 | REF. | – | 1 | – | – |
Male | 1.8 | [0.92–3.50] | 0.0888 | 1.4 | [0.92–2.3] | 0.115 | 0.87 | [0.42–1.80] | 0.7 | |
Cancer location | Digestive | 1 | REF. | – | 1 | REF. | – | 1 | – | – |
Head and Neck | 1.2 | [0.42–3.60] | 0.701 | 0.78 | [0.31–2.0] | 0.593 | 0.44 | [0.089–2.1] | 0.29 | |
Breast | 0.38 | [0.14–1.00] | 0.0613 | 0.68 | [0.37–1.3] | 0.219 | 0.71 | [0.26–1.90] | 0.49 | |
Disease severity | Local disease | 1 | REF. | – | 1 | REF. | – | 1 | – | – |
Advanced disease | 2.60 | [1.00–6.80] | 0.0462 | 2.2 | [1.2–3.90] | 0.00797 | 0.29 | [0.11–0.74] | 0.008 | |
Other chemotherapy before FP | No | 1 | REF. | – | 1 | REF. | – | 1 | – | – |
Yes | 1.2 | [0.59–2.50] | 0.606 | 2.1 | [1.3–3.30] | 0.00227 | 0.22 | [0.09–0.54] | 0.00069 | |
FP-based treatment | CAP | 1 | REF. | – | 1 | REF. | – | 1 | – | – |
FU | 0.90 | [0.40–2.00] | 0.798 | 1.5 | [0.8–2.60] | 0.217 | 0.83 | [0.34–2.00] | 0.68 | |
FU_CAP | 0.74 | [0.28–1.90] | 0.54 | 1.7 | [0.87–3.3] | 0.124 | 0.41 | [0.14–1.20] | 0.095 | |
FP-based toxicity | No | 1 | REF. | – | 1 | REF. | – | 1 | – | – |
Yes | 0.83 | [0.41–1.70] | 0.597 | 0.93 | [0.58–1.5] | 0.759 | 0.64 | [0.31–1.30] | 0.23 | |
Surgery associated to FP | No | 1 | REF. | – | 1 | REF. | – | 1 | – | – |
Yes | 0.46 | [0.23–0.93] | 0.0309 | 0.92 | [0.55–1.6] | 0.756 | 1.7 | [0.74–3.80] | 0.2 | |
Radiotherapy associated to FP | No | 1 | REF. | – | 1 | REF. | – | 1 | – | – |
Yes | 0.58 | [0.29–1.20] | 0.127 | 0.66 | [0.41–1.1] | 0.0797 | 1.2 | [0.55–2.40] | 0.7 | |
Observed complete response during FP treatment | No | 1 | REF. | – | – | – | – | – | – | – |
Yes | 0.098 | [0.037–0.25] | < 0.0001 | – | – | – | – | – | – | |
Any recurrence | No | 1 | REF. | – | – | – | – | – | – | – |
Yes | 5.00 | [1.70–14.0] | 0.00265 | – | – | – | – | – | – | |
Age at FP-based treatment | 1.04 | [1.01–1.07] | 0.0062 | 1.03 | [1.01–1.05] | 0.0069 | 0.98 | [0.95–1.01] | 0.21 | |
Number of chemotherapy lines | 0.93 | [0.80–1.07] | 0.31 | 1.08 | [0.99–1.16] | 0.065 | 0.86 | [0.74–1.01] | 0.06 | |
Number of FP cycles | 0.99 | [0.96–1.02] | 0.56 | 1.03 | [1.02–1.05] | < 0.001 | 0.98 | [0.95–1.01] | 0.30 | |